Cargando…
Aspartic Aminopeptidase Is a Novel Biomarker of Aggressive Chronic Lymphocytic Leukemia
Treatment of chronic lymphocytic leukemia has advanced substantially as our understanding of the kinase signal transduction pathways driven by the B cell receptor (BcR) has developed. Particularly, understanding the role of Bruton tyrosine kinase and phosphatidyl inositol 3 kinase delta in driving p...
Autores principales: | Kakodkar, Pramath, More, Sanket, András, Kinga, Papakonstantinou, Nikos, Kelly, Sharon, Makrooni, Mohammad Adib, Ortutay, Csaba, Szegezdi, Eva |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408864/ https://www.ncbi.nlm.nih.gov/pubmed/32664705 http://dx.doi.org/10.3390/cancers12071876 |
Ejemplares similares
-
A 2-Year Retrospective Case Series on Isolates of the Emerging Pathogen Actinotignum schaalii from a Canadian Tertiary Care Hospital
por: Kakodkar, Pramath, et al.
Publicado: (2022) -
A Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019 (COVID-19)
por: Kakodkar, Pramath, et al.
Publicado: (2020) -
The histone methyltransferase EZH2 as a novel prosurvival factor in clinically aggressive chronic lymphocytic leukemia
por: Papakonstantinou, Nikos, et al.
Publicado: (2016) -
The TΑp63/BCL2 axis represents a novel mechanism of clinical aggressiveness in chronic lymphocytic leukemia
por: Laidou, Stamatia, et al.
Publicado: (2022) -
Co-acting gene networks predict TRAIL responsiveness of tumour cells with high accuracy
por: O’Reilly, Paul, et al.
Publicado: (2014)